Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at
three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable
asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation
aerosol delivery.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan